Isoindoline Compounds for Alzheimer's Biomarker Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease are inadequate in effectively managing the condition, particularly in reducing the expression of specific biomarkers in the cerebral spinal fluid.
Innovation Solution
Administration of a therapeutically effective amount of a compound according to Formula I, which includes various substituents such as alkyl, hydroxy, and halo groups, to subjects in need of Alzheimer's disease treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease are used, then general disease management is maintained, but the expression of specific biomarkers (CHI3L1, CLU) in cerebral spinal fluid is not effectively reduced
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of isoindoline compounds through various substituents (R1-R11 groups including alkyl, hydroxy, and halo groups) to optimize their ability to reduce biomarker expression. The compound of Formula I represents a specific parameter configuration that achieves superior reduction of CHI3L1 and CLU biomarkers compared to existing treatments.
2Reliability
If a therapeutically effective amount of compound Formula I is administered, then biomarker expression is reduced, but potential side effects and treatment complexity may increase
Solution Approach 1:
The compound of Formula I demonstrates multi-functionality by simultaneously targeting multiple biomarkers (CHI3L1 and CLU) in cerebral spinal fluid through a single therapeutic agent. This universal approach allows one compound to address multiple aspects of Alzheimer's pathology, reducing the need for multiple separate treatments.
Data Source
AI summary
The present invention is directed to methods of treating Alzheimer's disease in a subject in need thereof. Also disclosed are methods of identifying novel compounds that may be useful in the treatment and prevention of Alzheimer's disease. Also disclosed are methods of determining the Alzheimer's disease status of a subject.